PRL and cancer: GDF15 has been shown to activate the MAPK/ERK1/2 signaling cascade through increased ERK1/2 phosphorylation in various cell types, including cancer cells; although a direct connection to prolactin signaling has not been established, it is possible that this pathway is regulated indirectly or as a secondary response.